Also known as: Acadia Pharmaceuticals, ACADIA Pharmaceuticals
ACADIA Pharmaceuticals' stock jumped after the European Medicines Agency recommended approval of its Rett syndrome drug Daybue. The company also reported strong quarterly results and progress on its Alzheimer's disease psychosis treatment.
The Consolidated Appropriations Act of 2026 extends the FDA's authority to award rare pediatric disease priority review vouchers through September 30, 2029, restoring a key incentive for developing therapies for rare pediatric diseases.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07284667 |
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response |
RECRUITING | PHASE2 |
| NCT07095465 |
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis |
ENROLLING_BY_INVITATION | PHASE3 |
| NCT07029581 |
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis |
RECRUITING | PHASE2 |
| NCT06420297 |
OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome |
TERMINATED | PHASE3 |
| NCT06194799 |
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study |
ENROLLING_BY_INVITATION | PHASE3 |
| NCT06159673 |
ACP-204 in Adults With Alzheimer's Disease Psychosis |
RECRUITING | PHASE2/PHASE3 |
| NCT05357612 |
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases |
RECRUITING | PHASE4 |
